FORM PTO-1449 U.S. DEPARTMENT OF COMME PATENT AND TRADEMARK OFF					ATTY. DOCKET NO.: S AR02366USACON3			SERIAL NO.: TO BE ASSIGNED	
INFORMATION DISCLOSURE STATEME FOR PATENT				TEMENT	APPLICANT: George GUITTARD, et al.				
	<i>,,</i> ,		. :f		FILING DATE:		GROUP:		
	(0.	se several sheets		ary)	Herewi	th	to b	e assigned	
			U.S. P	ATENT DOCU	MENTS			•	
*EXAMINER INITIAL	DOCUMENT NUMBER		DATE	NAME		CLASS	SUB- CLASS	FILING DATE IF	
KG	AA	6,262,115	07/17/01	GUITTARD et al	<u> </u>				
1	AB	6,124,355	09/26/00	GUITTARD et al					
	AC	5,912,268	06/15/99	GUITTARD et al	- 				
	AD	5,840,754	11/24/98	GUITTARD et al					
	AE	5,811,126	09/22/98	KRISHNAMURT	HY				
	AF	5,674,895	10/07/97	GUITTARD et al					
	AG	5,399,359	03/21/95	BAICHWAL					
	AH	4,902,514	02/20/90	BARCLAY et al.					
	AI	4,863,456	09/05/89	STEPHENS et al.					
	AJ	4,853,229	08/01/89	THEEUWES					
	AK	4,824,675	04/25/89	WONG et al.					
	AL 4,816,263 03/28/89 AYER AM 4,783,337 11/08/88 WONG		AYER et al.						
			11/08/88	WONG et al.	-				
			06/21/88	MEHTA					
	AO	4,721,613	01/26/88	URQUHART et a	al.				
	AP	4,612,008	09/16/86	WONG et al.					
	AQ	4,434,153	02/28/84	URQUHART et a	al.				
	AR	4,327,725	05/04/82	CORTESE et al.					
	AS	4,285,987	08/25/81	AYER et al.					
	AT	4,200,098	04/29/80	AYER et al.					
	ΑU	4,111,202	09/05/78	THEEUWES	•				
	AV	4,093,709	06/06/78	CHOI et al.					
	AW	4,088,864	05/09/78	THEEUWES et a	al.				
	AX	4,083,949	04/11/78	BENEDIKT					
	AY	4,079,038	03/14/78	CHOI et al.					
	AZ	4,070,347	01/24/78	SCHMITT					
	ВА	4,066,747	01/03/78	CAPOZZA					
			SAUNDERS et a	al.					
KG	ВС	3,992,518	11/16/76	CHEIN et al.					
EXAMINE	16	to		CONSIDERED 11 / 2005	•••	1050 000	D		
through cital applicant.	⊀: Ini ation	tial if reference cons if not in conformance	and not co	ner or not citation nsidered. Include	copy of this for	n with ne	xt comm	unication to	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			ATTY. DOCKET NO.: AR02366USACON3		SERIAL NO.: TO BE ASSIGNED				
INFORMATION DISCLOSURE STATEMENT			APPLICANT:						
FOR PATENT			George GUITTARD, et al.						
(Use several sheets if necessary)			FILING DATE: Herewith		GROUP: to be assigned				
	U.S. PATENT DOCUM					100	e assigi	-	
V.C	BD	3,962,414	0.5. F/	MICHAELS	VIENTS	r	T		
K6	BE	3,916,899	11/04/75	THEEUWES et a	<u> </u>			<u> </u>	
 	BF	3,845,770	11/05/74	THEEUWES et a				· · · · · · · · · · · · · · · · · · ·	
	BG	3,811,444	05/21/74	HELLER et al.		 	 		
	ВН	3,139,383	06/30/64	NEVILLE		<u> </u>		ļ	
 	BI	2,996,431	08/16/61	BARRY					
K6	BJ	2,799,242	07/16/57	WURSTER					
			FORFIGN	PATENT DOC	UMENTS			•	
	1	DOCUMENT	DATE	COUNTRY	7011121110	CLASS	SUB-	TRANS	LATION
		NUMBER					CLASS	YES	NO
166	ВК	}	11/28/96	PCT			ļ	X	
KG	BL	WO 96/12477	05/02/96	PCT		<u> </u>	<u> </u>	X	<u> </u>
	OT	HER DOCUMEN	TS (Includ	ling Author, Titl	e, Date, Pert	inent Pa	ages, Et	c.)	
	ВМ	Michael M. Colema							
K6		"A Practical Guide t			<u> </u>				
	BN	KODAMA KK, <u>DAT</u> , "Sustained release	preparation	of oxybutynin chlo	Derwent Public ride - comprise	ations Ltd s oxybuty	I., Jan. 18 nin chlori	3, 1994. de, acid	ic
	<u> </u>	substance, gelling agent and higher alchohol"							
1 1	ВО	KODAMA KK, DATABASE WPI, AN: 94-031722, Derwent Publications Ltd., Dec. 21, 1993.							
1 1			rmaceutical preparations for prolonged action against urinary incontinence – comprise ained release oxybutynin chloride for pharmaceutical compsn. sustained release coating film						
		of non water soluble	ple polymers and/or ethylcellulose"						
	ВР			ostracts, 120(18):227011, May 2, 1994. on of oxybutynin chloride"					
	BQ	Enomoto, et al., <u>Chemical Abstracts</u> , 120(14):173499, April 4, 1994.							
			"Sustained release formulations containing oxybutynin chloride"						
	BR	Julian H. Fincher, <u>J. Pharm Sci.</u> , 57(11):1825-1835, November 1968. "Particle Size of Drugs and Its Relationship to Absorption and Activity"							
	BS	P. Grafton, Modern Plastics Encyclopedia, 46:62-70, 1969. "General principles for designing with plastics"							
	ВТ	Suneel K. Gupta, et al., <u>Clinical Pharmacology & Therapeutics</u> , 61(2):Abstract PIV-26, 1997. "Evidence of Site Specific Presystemic Methabolism of Oxybutynin Following Oral Administration"							
1	BU	K.W. Leong & R. Langer, et al., Advanced Drug Delivery Reviews, 1:199-233, 1987.							
	"Polymeric controlled drug delivery"								
K6	Robert J. Linhardt, <u>Controlled Release of Drugs: Polymers and Aggregate Systems</u> , Ch.2, pp.53-95, 1989. "Biodegradable Polymers for Controlled Release of Drugs"								эр.53-
EXAMINER DATE CONSIDERED									
	Į,	CotaMa			11/2005				
		tial if reference consi							
	tation	if not in conformance	and not co	nsidered. Include	copy of this form	n with ne	xt commu	unication	ı to
applicant.									

FORM	FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				ATTY. DOCKET NO.: AR02366USACON3	SERIAL NO.: TO BE ASSIGNED			
1	NFC	RM	ATION DISCLOSURE STATEMENT FOR PATENT	APPLICANT: Georg GUITTARD, et al.					
		(U	se several sheets if necessary)	FILING DATE: Herewith	GROUP: to be assigned				
		OTI	HER DOCUMENTS (Including Author,	Title	e, Date, Pertinent Pa	iges, Etc.)			
K	BW S.M. Lu & Jun-Ying Yu, Inter. J. Pharm., 112:117-124, 1994. "Dimensionless Presentation for Drug Release from a Coated Pure Drug Bead: 2 Experimen								
		ВХ	Carl Gustaf Nilsson, et al., Neurourology and Urodynamics, 16(6):533 542, 1997. "Comparison of a 10-mg Controlled Release Oxybutynin Tablet with a 5-mg Oxybutynin Tablet in Urge Incontinent Patients"						
	_	BY	Remington's Pharmaceutical Sciences, 14 th E Publishing Company, Easton, FA 1970.	ditio	n, Ch.86 "Powders", pp	1626-1648, Mack			
		BZ	Remington's Pharmaceutical Sciences, 17 th Ed., Ch 35, "Dissolution", pp 653-666, and Ch. 90, "Oral Solid Dosage Forms", pp. 1603-1625; Mack Publishing Company, Easton, PA 1985						
		CA	Roerdink, et al., <u>Drug Carrier Systems</u> , 9:57-1	109,	1989.				
		СВ	W.J. Roff et al., Handbook of Common Polym	<u>iers,</u>	CRC Press, Cleveland	Ohio, 1971.			
		CC	<u>The United States Pharmacopia - The National Formulary</u> , USP23:NF18, pp. 1791-1796, 1995. "<711> Dissolution"						
		CD	The United States Pharmacopia - The National Formulary, USP XXII / NF XVII, pp. 1578-1579, 1990. "<711> Dissolution"						
		CE	Dale E. Wurster, <u>J. Am. Pharm. Assoc</u> , 48(8):451-454, August 1959. "Air-Suspension Technique of Coating Drug Particles"						
KG	1	CF	Pale E. Wurster, J. Am. Pharm. Assoc, 49(2):82-84, February 1960. "Preparation of Compressed Tablet Granulations by the Air-Suspension Technique II"						
EXAMINER DATE CONSIDERED									
totanth a				11/2005					
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									

OIP	Ever
(OET 2 9	का उ
A TRAD	EMARTE

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office				Docket No. ALZA-0142	Application No. 10/645,467			
				Applicant George V. Guittard, et al. Filing Date August 20, 2003 Not Yet Assigned				
Examiner Initial	_	Document No.	Date	Name	Class	Subclass		
						<u> </u>		
	•	FOR	EIGN PATE	ENT DOCUMENTS	3			
Examiner						Translation		
Initial		Document No.	Date	Country	YES	NO		
KG	59	JP 5-339151	12/21/93	Japan	X			
KC	60	JP 6-9388	01/18/94	Japan	X			
EXAMINER		A=MC		DATE CONSIDE	RED 11/2005			





Form 1	PTO-	-1449 Modified	Docket No. ALZA-0142	Application No. 10/645,467			
C	ited b	t and Publications y Applicant heets if necessary)	Applicant George V. Guittard, et al.				
		nent of Commerce Trademark Office	Filing Date August 20, 2003	Group Not Yet Assigned			
			Confirmation No. Not Yet Assigned				
O 1	THE	R DOCUMENTS (Inclu	ding Author, Title, Da	ate, Pertinent Pages, Etc.)			
: K6	61	Anderberg, E.K., et al., "Physicochemical aspects of drug release – X. Investigation of the applicability of the cube root law for characterization of the dissolution rate of fine particulate materials," <i>International Journal of Pharmaceutics</i> , 1990, 62, 143-151					
K6	The United States Pharmacopeia/The National Formulary, "Test solutions," UPS 23/NF180, January 1, 1995, 2052-2053						
			,				
- III - III							
EXAMINER	K.	the	DATE C	CONSIDERED 4.16.2005			